Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S. - At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference
- How the 2024 elections can impact cancer policy
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- “Less Radical” podcast: Resistance to change, a data scandal
- FDA extends shelf-life for IV fluids in shortage after Hurricane Helene